OBJECTIVES: This study aims to analyse how treatment effect parameters such as Hazard Ratios (HR) impact HTA outcomes published by the Federal Joint Committee (G-BA) in Germany and National Authority for Health (HAS) in France for oncology treatments from 2015 to 2023.

METHODS: Desk research was used to analyse publicly available HTA reports from G-BA and HAS in oncology and key data such as study endpoints (Overall Survival (OS) HR), patient population submitted by manufacturer, final list price and benefit assessment outcome were extracted along with final prices.

RESULTS: In Germany, decreasing monthly price per patient was noticed as HR approached 1, irrespective of line of treatment & trial phases. Data maturity supersedes trial phase & line of treatment to achieve premium price. Comparator-controlled, Phase III programs are critical to achieve price points at or around €10,000 per patient per month. OS HR < 1, in a smaller patient population are ideal for premium pricing opportunity in GER. In France increasing HR towards 1 didn’t impact as significantly on monthly treatment cost. Line of treatment nor robustness of studies (Phases I/II vs. Phase III) have direct impact on monthly price per patient. As OS HR approaches 1 & beyond, monthly cost per patient tend to fall below €5,000, especially with increasing prevalence. OS HR < 1, in smaller patient population are ideal for premium pricing opportunity.

CONCLUSIONS: Analysis of HTAs suggests smaller patient volume continues to drive premium price. Irrespective of phases of trial(s), maturity of data is more critical and Phase-III based OS data continues to be the most compelling determinant for higher price. Achieving premium price strictly requires HR < 1 and lower patient volume, irrespective of niche/broader patient population.